What question did this study set out to answer?

To determine whether adding rituximab to standard chemotherapy improves clinical outcomes in younger adults diagnosed with CD20-positive, Philadelphia chromosome-negative acute lymphoblastic leukemia.

September 14, 2016New England Journal of MedicineOpen Access

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

View Full Paper

Ask AI

Bookmark

Authors

SMSébastien MauryAssistance Publique – Hôpitaux de Paris SCSylvie ChevretUniversité Claude Bernard Lyon 1 XTXavier ThomasHôpital Lyon Sud

Discussion

Member takes

Implication

Randomized trial demonstrates improved outcomes with rituximab addition in younger adults with CD20-positive, Ph-negative acute lymphoblastic leukemia, suggesting clear therapeutic benefits.

Key Points

To determine whether adding rituximab to standard chemotherapy improves clinical outcomes in younger adults diagnosed with CD20-positive, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Randomized clinical trial (ClinicalTrials.gov number NCT00327678) conducted in younger adult patients with CD20-positive, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Evaluated the therapeutic addition of rituximab to an acute lymphoblastic leukemia chemotherapy protocol.
The addition of rituximab to the chemotherapy protocol significantly improved clinical outcomes in younger adults with CD20-positive, Ph-negative acute lymphoblastic leukemia; specific event rates, effect sizes, and p-values were not reported in the abstract.

Cite This Study

Maury et al. (2016) studied this question.

synapsesocial.com/papers/69936e1f53522ac2836263ea https://doi.org/10.1056/nejmoa1605085

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates improved outcomes with rituximab addition in younger adults with CD20-positive, Ph-negative acute lymphoblastic leukemia, suggesting clear therapeutic benefits.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider